Warburg Research Analysts Give Rhoen Klinikum (RHK) a €25.20 Price Target

Warburg Research set a €25.20 ($31.11) price target on Rhoen Klinikum (ETR:RHK) in a research report released on Wednesday. The firm currently has a neutral rating on the stock.

A number of other brokerages have also weighed in on RHK. DZ Bank restated a sell rating on shares of Rhoen Klinikum in a report on Wednesday, December 13th. Deutsche Bank set a €22.00 ($27.16) price objective on shares of Rhoen Klinikum and gave the stock a neutral rating in a report on Monday, January 22nd. Credit Suisse Group set a €23.50 ($29.01) price objective on shares of Rhoen Klinikum and gave the stock a sell rating in a report on Thursday, March 8th. Cfra set a €25.00 ($30.86) price objective on shares of Rhoen Klinikum and gave the stock a sell rating in a report on Tuesday, February 27th. Finally, Berenberg Bank set a €29.15 ($35.99) price objective on shares of Rhoen Klinikum and gave the stock a neutral rating in a report on Friday, February 23rd. Five equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. Rhoen Klinikum currently has a consensus rating of Hold and an average price target of €24.55 ($30.30).

How to Become a New Pot Stock Millionaire

Shares of ETR RHK opened at €26.28 ($32.44) on Wednesday. Rhoen Klinikum has a twelve month low of €25.08 ($30.96) and a twelve month high of €32.12 ($39.65).

ILLEGAL ACTIVITY WARNING: “Warburg Research Analysts Give Rhoen Klinikum (RHK) a €25.20 Price Target” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/warburg-research-analysts-give-rhoen-klinikum-rhk-a-25-20-price-target.html.

Rhoen Klinikum Company Profile

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services in the areas of cardiological and coronary diseases, neurological disorders, oncology, lung diseases, and orthopedic and accident surgeries; rehabilitation services; and thoracic, pulmonary and vascular diseases, tumors, heart conditions, and nervous and skeletal system diseases.

Analyst Recommendations for Rhoen Klinikum (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply